Results 61 to 70 of about 15,427 (288)

Impact of Adverse Events Associated With Acitretin Treatment of Moderate-to-Severe Plaque Psoriasis: Based on an Observational, Single-Center Study in Shanghai, China

International Journal of Dermatology and Venerology, 2023
Objective:. Acitretin is a widely used systemic retinoid that is to treat psoriasis but has significant variations in efficacy and adverse events (AEs) among individuals. This study aimed to determine the impact of AEs associated with acitretin treatment
Xiao-Yuan Zhong, Ying Li, Rui Ma, Xin Wang, Ying-Yuan Yu, Ning Yu, Yang-Feng Ding, Jia-Jing Lu, Yu-Ling Shi   +8 more
doaj   +1 more source

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation [PDF]

, 2017
Background: Psoriasis is a chronic inflammatory disease that predominantly affects the skin. Adalimumab (HUMIRA®, AbbVie, Maidenhead, UK), etanercept (Enbrel®, Pfizer, New York, NY, USA) and ustekinumab (STELARA®, Janssen Biotech, Inc., Titusville, NJ ...
AbbVie, Ali, All Wales Medicines Strategy Group, All Wales Therapeutics and Toxicology Centre, Altmeyer, Amgen Inc, Amgen Inc, Amgen Inc, Amgen Inc, Amornpinyokeit, Asahina, Balzola, Barker, Basko-Plluska, Basra, Benoit, Berth-Jones, Bigby, Bissonnette, Bonafede, Brunasso, Brănişteanu, Burden-Teh, Burden-Teh, Burden-Teh, Burmester, Burmester, Centre for Reviews and Dissemination, Chaudhari, Chen, Chingcuanco, Chiu, Christiansen, Christophers, Cooper, Corbett, da Silva, Dakin, de Jager, De Jager, de Jager, Department of Health, Dias, Dias, Dias, Dias, DiMarco, Dixon, Dolan, Driessen, Eissing, Elder, Elewski, Esposito, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, EuroQol Research Foundation, Faerber, Fallah Arani, Famenini, Farhi, Feldman, Flytström, Fonia, Garber, Geiger, Gisondi, Gniadecki, Gniadecki, Gordon, Gordon, Gottlieb, Gottlieb, Greater Medicines Management Group, Griffiths, Guenther, Heydendael, Heydendael, Higgins, Higgins, Ho, Holme, Howe, Ibfelt, Ibrahim, Igarashi, Italian Multicenter Study Group on Cyclosporin in Psoriasis, Janagond, Jankovic, Janssen Biotech, Inc, Janssen Research & Development, LLC, Janssen Research & Development, LLC, Janssen Research & Development, LLC, Janssen-Cilag International, Joint Formulary Committee, Khan, Kim, Kim, Kimball, Klufas, Koo, Kragballe, Krueger, Krueger, Kurd, Laburte, Landells, Landells, Landells, Langley, Langley, Langley, Langley, Lara-Corrales, Lebwohl, Lebwohl, Lefebvre, Lefebvre, Leman, Leonardi, Leonardi, Levy, Lewis-Jones, Lu, Lynde, López-Ferrer, Mahé, Meffert, Melis, Menter, Menter, Menter, MIMS, Moher, National Horizon Scanning Centre, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, NIHR Horizon Scanning Centre, NIHR Horizon Scanning Centre, Norman, Novartis Pharmaceuticals, Novartis Pharmaceuticals, Office for National Statistics, Oostveen, Paller, Paller, Paller, Paller, Paller, Paller, Paller, Paller, Paller, Papp, Papp, Papp, Papp, Papp, Papp, Papp, Papp, Papp, Parisi, Park, Paul, Pereira, Pfizer, Pfizer, Phillipp, Puig, Ranjan, Reich, Reich, Rencz, Revicki, Richardson, Rodgers, Romero-Maté, Royal College of Paediatrics and Child Health, Ruano, Ruzicka, Ryan, Salek, Sanclemente, Saurat, Schabert, Seminara, Seyger, Shah, Siegfried, Siegfried, Signorovitch, Smith, Soliman, Strand, Strohal, Strohal, Sutton, Takashima, Tanew, Tarp, Torii, Tsai, Umezawa, Upton, US Food and Drug Administration, van de Kerkhof, van Reenen, Varni, Varni, Varni, Vencovsky, Vickers, Warren, Warren, Woods, Woolacott, Wu, Wyeth, Yang, Young, Zachariae, Zhu   +239 more
core   +3 more sources

Hidradenitis suppurativa: miért nem tartozik az acne csoportba? [PDF]

, 2018
L
Baltás, Eszter, Kinyó, Ágnes, Kovács, Réka, Töröcsik, Dániel   +3 more
core   +1 more source

Fixed tapering dosage of acitretin in patients with psoriasis: A short-term analysis of clinical efficacy and its effects on biochemical parameters

Indian Journal of Dermatology, 2019
Background: Acitretin is a widely used systemic retinoid in the treatment of psoriasis. Dosage of acitretin in not weight adjusted due to certain interindividual variations.
Varadraj V Pai, Diksha Phadke, Pankaj Shukla, Krupeksha Naik   +3 more
doaj   +1 more source

Evaluation of COVID-19 risk in patients on systemic retinoid therapy

Turkderm Turkish Archives of Dermatology and Venereology, 2022
Background and Design: Systemic retinoids are commonly used medications in dermatology and indicated in various skin disorders such as acne vulgaris and psoriasis.
Emine Müge Acar, Kemal Özyurt, Rukiye Akyol   +2 more
doaj   +1 more source

Drug survival and safety profile of acitretin monotherapy in patients with psoriasis: A multicenter retrospective study

Dermatologic Therapy, 2021
Acitretin is a nonimmunosuppresive systemic agent used in the treatment of psoriasis. Despite its frequent use, research on drug survival and adverse effects is limited.
A. Kara Polat, İ. Oğuz Topal, Melek Aslan Kayıran, A. E. Koku Aksu, S. Aytekin, F. Topaloğlu Demir, Tugba Ozkok Akbulut, İ. Kıvanç Altunay, Ezgi Erdal Ozkur, A. Karadağ   +9 more
semanticscholar   +1 more source

The Impact of Methotrexate on Cardiovascular Outcomes in Psoriasis: A Systematic Review and Meta‐Analysis

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis is a chronic immune‐mediated inflammatory disease with a global prevalence of 2%–3% and 1.3% in Brazil. It is associated with comorbidities such as obesity, hypertension, and diabetes, all of which contribute to increased cardiovascular risk due to systemic inflammation and endothelial dysfunction.
Tiago A. S. Costa, Sheila T. K. Medorima, Renata F. Magalhães   +2 more
wiley   +1 more source

Unravelling the Major Cardiovascular Risks of Systemic Psoriasis Medications: A Literature Systematic Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis is a chronic inflammatory dermatological condition associated with an elevated risk of cardiovascular events (CVEs). Systemic therapies have transformed disease management, but their cardiovascular (CV) safety profiles remain incompletely understood and inconsistently reported.
Mai Thi Hoai Son, Yves Julien Mbama Biloa, Pauline Gouttefarde, Thomas Franck, Gilles Cizeron, Mathieu Oriol, François Maccari, Elisa Cinotti, Beatrice Trombert‐Paviot, Bienvenu Bongue, Jean‐Luc Perrot   +10 more
wiley   +1 more source

Dermatology [PDF]

, 2004
Dermatology continues to develop at a steady pace. In the past few years there have been exciting advances in our understanding of skin structure and function in health and disease and progress in genetics, epidemiology, immunology, pharmacology and ...
Boffa, Michael J.
core   +1 more source

Small intestine perforation in a 58-year-old man with Darier disease after 25 months of oral acitretin therapy

Dermatologica Sinica, 2014
Darier disease is a rare autosomal dominant disease characterized by abnormal keratinization of the epidermis, mucosa, and nails. Acitretin, an aromatic form of tretinoin, is widely prescribed in the treatment of Darier disease.
Yi-Hao Wang, Dino Tsai
doaj   +1 more source